Insiders Immunome, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-12 pm EDT			5-day change	1st Jan Change
16 ^USD	+1.91%		+2.89%	+49.53%

May. 31	Piper Sandler Initiates Immunome With Overweight Rating, $27 Price Target	MT
May. 21	Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing	MT

Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing	May. 21	MT
Immunome Appoints Max Rosett as CFO	May. 17	MT
Immunome, Inc. Appoints Kinney Horn as Chief Business Officer	May. 02	CI
Immunome, Inc. Announces Executive Changes	Apr. 30	CI
Immunome, Inc. Appoints Sandra M. Swain to Board of Directors	Apr. 25	CI
Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations	Feb. 01	CI
Immunome Appoints Phil Roberts as Chief Technical Officer	Jan. 04	MT
Immunome Appoints Phil Roberts as Chief Technical Officer	Jan. 04	CI
Immunome, Inc. Announces Board Changes	Jan. 02	CI
Immunome, Inc. Announces Executive Changes, Effective January 2, 2024	Dec. 29	CI
Immunome, Inc. Appoints Jean-Jacques Bienaimé to Board of Directors	Nov. 08	CI
Immunome Appoints Bob Lechleider as Chief Medical Officer	23-10-19	CI
Immunome Insider Bought Shares Worth $999,996, According to a Recent SEC Filing	23-10-04	MT
Immunome Insider Bought Shares Worth $249,993, According to a Recent SEC Filing	23-10-04	MT
Immunome, Inc. Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board	23-02-08	CI
Insider Buy: Immunome	21-09-14	MT
Insider Buy: Immunome	21-09-13	MT
Immunome, Inc. Announces Executive Changes	21-08-05	CI
Immunome, Inc. Appoints Andrew D. Badley to its COVID-19 Advisory Board	21-06-30	CI
Immunome, Inc. Announces Board Changes	21-06-17	CI

No results for this search